Evidence map›Paper›PMID 33605517›Full record

ReviewCancer science2021

Dysregulation of Wnt/β-catenin signaling by protein kinases in hepatocellular carcinoma and its therapeutic application.

Qian Li, Mengqing Sun, Menglan Wang, Mengqing Feng, Fan Yang, Lina Li, Jianbo Zhao, Cunjie Chang, Heng Dong, Tian Xie and 1 more

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Cancer science, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.

0numbers the graph read from it
0cells of the map it votes in
33citing papers in PubMed
2.8field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

33 citing papers in PubMed, 45 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Review
  7. Review
  8. Article
  9. Article
  10. Article
  11. Review
  12. Review
  13. Article
  14. Review
  15. Article
  16. Review
  17. Genes · 2023
    Article
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 1 institution in 2 countries.

Qian LiKey Laboratory of Elemene Class Anti-Cancer Chinese Medicines, Engineering Laboratory of Development and Application of Traditional Chinese Medicines, Collaborative Innovation Center of Traditional Chinese Medicines of Zhejiang Province, Department of Hepatology, Institute of Hepatology and Metabolic Diseases, Institute of Integrated Chinese and Western Medicine for Oncology, The Affiliated Hospital of Hangzhou Normal University, College of Pharmacy, School of Medicine, Hangzhou Normal University, Hangzhou, China.ORCID https://orcid.org/0000-0002-2560-5730
Mengqing SunKey Laboratory of Elemene Class Anti-Cancer Chinese Medicines, Engineering Laboratory of Development and Application of Traditional Chinese Medicines, Collaborative Innovation Center of Traditional Chinese Medicines of Zhejiang Province, Department of Hepatology, Institute of Hepatology and Metabolic Diseases, Institute of Integrated Chinese and Western Medicine for Oncology, The Affiliated Hospital of Hangzhou Normal University, College of Pharmacy, School of Medicine, Hangzhou Normal University, Hangzhou, China.
Menglan WangKey Laboratory of Elemene Class Anti-Cancer Chinese Medicines, Engineering Laboratory of Development and Application of Traditional Chinese Medicines, Collaborative Innovation Center of Traditional Chinese Medicines of Zhejiang Province, Department of Hepatology, Institute of Hepatology and Metabolic Diseases, Institute of Integrated Chinese and Western Medicine for Oncology, The Affiliated Hospital of Hangzhou Normal University, College of Pharmacy, School of Medicine, Hangzhou Normal University, Hangzhou, China.
Mengqing FengKey Laboratory of Elemene Class Anti-Cancer Chinese Medicines, Engineering Laboratory of Development and Application of Traditional Chinese Medicines, Collaborative Innovation Center of Traditional Chinese Medicines of Zhejiang Province, Department of Hepatology, Institute of Hepatology and Metabolic Diseases, Institute of Integrated Chinese and Western Medicine for Oncology, The Affiliated Hospital of Hangzhou Normal University, College of Pharmacy, School of Medicine, Hangzhou Normal University, Hangzhou, China.
Fan YangKey Laboratory of Elemene Class Anti-Cancer Chinese Medicines, Engineering Laboratory of Development and Application of Traditional Chinese Medicines, Collaborative Innovation Center of Traditional Chinese Medicines of Zhejiang Province, Department of Hepatology, Institute of Hepatology and Metabolic Diseases, Institute of Integrated Chinese and Western Medicine for Oncology, The Affiliated Hospital of Hangzhou Normal University, College of Pharmacy, School of Medicine, Hangzhou Normal University, Hangzhou, China.
Lina LiKey Laboratory of Elemene Class Anti-Cancer Chinese Medicines, Engineering Laboratory of Development and Application of Traditional Chinese Medicines, Collaborative Innovation Center of Traditional Chinese Medicines of Zhejiang Province, Department of Hepatology, Institute of Hepatology and Metabolic Diseases, Institute of Integrated Chinese and Western Medicine for Oncology, The Affiliated Hospital of Hangzhou Normal University, College of Pharmacy, School of Medicine, Hangzhou Normal University, Hangzhou, China.
Jianbo ZhaoKey Laboratory of Elemene Class Anti-Cancer Chinese Medicines, Engineering Laboratory of Development and Application of Traditional Chinese Medicines, Collaborative Innovation Center of Traditional Chinese Medicines of Zhejiang Province, Department of Hepatology, Institute of Hepatology and Metabolic Diseases, Institute of Integrated Chinese and Western Medicine for Oncology, The Affiliated Hospital of Hangzhou Normal University, College of Pharmacy, School of Medicine, Hangzhou Normal University, Hangzhou, China.
Cunjie ChangKey Laboratory of Elemene Class Anti-Cancer Chinese Medicines, Engineering Laboratory of Development and Application of Traditional Chinese Medicines, Collaborative Innovation Center of Traditional Chinese Medicines of Zhejiang Province, Department of Hepatology, Institute of Hepatology and Metabolic Diseases, Institute of Integrated Chinese and Western Medicine for Oncology, The Affiliated Hospital of Hangzhou Normal University, College of Pharmacy, School of Medicine, Hangzhou Normal University, Hangzhou, China.
Heng DongKey Laboratory of Elemene Class Anti-Cancer Chinese Medicines, Engineering Laboratory of Development and Application of Traditional Chinese Medicines, Collaborative Innovation Center of Traditional Chinese Medicines of Zhejiang Province, Department of Hepatology, Institute of Hepatology and Metabolic Diseases, Institute of Integrated Chinese and Western Medicine for Oncology, The Affiliated Hospital of Hangzhou Normal University, College of Pharmacy, School of Medicine, Hangzhou Normal University, Hangzhou, China.
Tian XieKey Laboratory of Elemene Class Anti-Cancer Chinese Medicines, Engineering Laboratory of Development and Application of Traditional Chinese Medicines, Collaborative Innovation Center of Traditional Chinese Medicines of Zhejiang Province, Department of Hepatology, Institute of Hepatology and Metabolic Diseases, Institute of Integrated Chinese and Western Medicine for Oncology, The Affiliated Hospital of Hangzhou Normal University, College of Pharmacy, School of Medicine, Hangzhou Normal University, Hangzhou, China.
Jianxiang ChenKey Laboratory of Elemene Class Anti-Cancer Chinese Medicines, Engineering Laboratory of Development and Application of Traditional Chinese Medicines, Collaborative Innovation Center of Traditional Chinese Medicines of Zhejiang Province, Department of Hepatology, Institute of Hepatology and Metabolic Diseases, Institute of Integrated Chinese and Western Medicine for Oncology, The Affiliated Hospital of Hangzhou Normal University, College of Pharmacy, School of Medicine, Hangzhou Normal University, Hangzhou, China.
Affiliated Hospital of Hangzhou Normal University · CN

Funding

National Natural Science Foundation of China 81730108National Natural Science Foundation of China 81802338National Natural Science Foundation of China 81802831National Natural Science Foundation of China 81902507National Natural Science Foundation of China 81973635National Natural Science Foundation of China 82072646Start-up Grant of HZNU 4125C5021820470Zhejiang Provincial Natural Science Foundation of China LR21H160001Zhejiang Provincial Natural Science Foundation of China LY21H160043Zhejiang Provincial Natural Science Foundation of China LY21H160044
6 · The paper itself

Abstract

Wnt/β-catenin signaling is indispensable for many biological processes, including embryonic development, cell cycle, inflammation, and carcinogenesis. Aberrant activation of the Wnt/β-catenin signaling can promote tumorigenicity and enhance metastatic potential in hepatocellular carcinoma (HCC). Targeting this pathway is a new opportunity for precise medicine for HCC. However, inhibiting Wnt/β-catenin signaling alone is unlikely to significantly improve HCC patient outcome due to the lack of specific inhibitors and the complexity of this pathway. Combination with other therapies will be an important next step in improving the efficacy of Wnt/β-catenin signaling inhibitors. Protein kinases play a key and evolutionarily conserved role in the Wnt/β-catenin signaling and have become one of the most important drug targets in cancer. Targeting Wnt/β-catenin signaling and its regulatory kinase together will be a promising HCC management strategy. In this review, we summarize the kinases that modulate the Wnt/β-catenin signaling in HCC and briefly discuss their molecular mechanisms. Furthermore, we list some small molecules that target the kinases and may inhibit Wnt/β-catenin signaling, to offer new perspectives for preclinical and clinical HCC studies.

Indexed as

Axin Signaling Complexbeta CateninCarcinoma, HepatocellularCDC2 Protein KinaseCombined Modality TherapyCreatine KinaseCyclin-Dependent KinasesErbB ReceptorsFocal Adhesion Kinase 1Glycogen Synthase Kinase 3 betaHumansLiver NeoplasmsLow Density Lipoprotein Receptor-Related Protein-5Low Density Lipoprotein Receptor-Related Protein-6MAP Kinase Kinase Kinase 7MAP Kinase Kinase KinasesAxin Signaling Complexbeta CateninCDC2 Protein KinaseCDK14 protein, humanCDK1 protein, humanCreatine KinaseCyclin-Dependent KinasesEGFR protein, humanErbB ReceptorsFocal Adhesion Kinase 1Glycogen Synthase Kinase 3 betaLow Density Lipoprotein Receptor-Related Protein-5Low Density Lipoprotein Receptor-Related Protein-6LRP5 protein, humanLRP6 protein, humanMAP Kinase Kinase Kinase 7MAP Kinase Kinase KinasesMET protein, humanNEK2 protein, humanNIMA-Related Kinasesp21-Activated KinasesPAK4 protein, humanProtein Kinase InhibitorsProtein KinasesProtein Serine-Threonine KinasesProto-Oncogene Proteins c-metPTK2 protein, humanReceptor Protein-Tyrosine KinasesReceptor Tyrosine Kinase-like Orphan ReceptorsROR2 protein, humanSIK1 protein, humansrc-Family KinasesWnt Proteinscombination therapyhepatocellular carcinomaprotein kinasesmall moleculeWntβ-catenin signaling

Identifiers

PMID33605517
PMCPMC8088956
OpenAlexW3131453240

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.